Back

Efficacy and safety of dronedarone vs placebo in patients with atrial fibrillation or atrial flutter across a spectrum of renal function: post hoc analyses of the EURIDIS-ADONIS trials

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Arrhythmias, General ePosters Antiarrhythmic Drug Treatment ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Munveer Thind

Lankenau Heart Institute, Wynnewood (United States of America)

100 More presentations in this session

Presentation thumbnail
Beneficial electrophysiologic effects of sacubitril in different arrhythmia syndromes
Professor G. Frommeyer (Munster, DE)
Abstract Slides
Presentation thumbnail
Inflammation of conduction tissue in patients with arrhythmic phenotype of myocarditis
Doctor A. Frustaci (Rome, IT)
Abstract Slides
Presentation thumbnail
The pleiotropic effect of a deleterious DES mutation in familial atrial fibrillation and the role of PDE4DIP as a genetic modifier for heart block
Doctor M. Abou Ziki (New Haven, US)
Abstract Slides
Presentation thumbnail
Gen-editing to model Short QT syndrome type 5 using human-induced pluripotent stem cell-derived cardiomyocytes
Mr L. Maywald (Mannheim, DE)
Abstract Slides
Presentation thumbnail
Inducibility of atrial fibrillation is associated with disturbed activation pattern in bachmanns bundle
Ms L. van Staveren (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Arrhythmias, General ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials
1 September 2019
thumbnail
Congress Presentation
Heart failure patients with severe chronic kidney disease: characterisation and prognostic predictors
22 May 2023
thumbnail
Congress Presentation
Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry- is dosing according to renal function appropriate?
27 August 2021
thumbnail
Congress Presentation
Predictors of contrast induced nephropathy in patients with normal renal function undergoing percutaneous coronary intervention - ADAPH score
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources